• 1
    Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 190020.
    Direct Link:
  • 2
    Modlin IM, Hunt RH, Malfertheiner P et al. Diagnosis and management of non-erosive reflux disease–the Vevey NERD Consensus Group. Digestion 2009; 80: 7488.
  • 3
    de Leone A, Tonini M, Dominici P, Grossi E, Pace F. The proton pump inhibitor test for gastroesophageal reflux disease: optimal cut-off value and duration. Dig Liver Dis 2010; 42: 78590.
  • 4
    Galmiche JP, Clouse RE, Balint A et al. Functional esophageal disorders. Gastroenterology 2006; 130: 145965.
  • 5
    Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)–acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 53745.
  • 6
    Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140: 51827.
  • 7
    Savarino E, Zentilin P, Tutuian R et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008; 103: 268593.
    Direct Link:
  • 8
    Savarino E, Pohl D, Zentilin P et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009; 58: 118591.
  • 9
    Surdea Blaga T, Dumitrascu D, Galmiche JP, Bruley des Varannes S. Functional heartburn: clinical characteristics and outcome. Eur J Gastroenterol Hepatol 2013; 25: 28290.
  • 10
    Zentilin P, Dulbecco P, Savarino E, Giannini E, Savarino V. Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux literature review. Dig Liver Dis 2004; 36: 5659.
  • 11
    Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58: 295309.
  • 12
    Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 65664.
  • 13
    Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil 2012; 24: 74757, e350.
  • 14
    Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut [Review]. 2012; 61: 134054.
  • 15
    Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease–current concepts and dilemmas. Am J Gastroenterol 2001; 96: 30314.
  • 16
    Ferrus JA, Zapardiel J, Sobreviela E. Management of gastroesophageal reflux disease in primary care settings in Spain: SYMPATHY I study. Eur J Gastroenterol Hepatol 2009; 21: 126978.
  • 17
    Geeraerts B, Vandenberghe J, Van Oudenhove L et al. Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology 2005; 129: 143744.
  • 18
    Miwa H, Inoue K, Ashida K et al. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 32332.
  • 19
    Savarino E, de Bortoli N, Zentilin P et al. Alginate controls heartburn in patients with erosive and nonerosive reflux disease. World J Gastroenterol 2012; 18: 43718.
  • 20
    Zentilin P, Iiritano E, Dulbecco P et al. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Dig Liver Dis 2006; 38: 22632.
  • 21
    Sifrim D. Acid, weakly acidic and non-acid gastro-oesophageal reflux: differences, prevalence and clinical relevance. Eur J Gastroenterol Hepatol 2004; 16: 82330.
  • 22
    Savarino E, Tutuian R, Zentilin P et al. Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. Am J Gastroenterol 2010; 105: 105361.
  • 23
    Kocian J, Kocianova J. Clinical experiences with preparation Hylakombun in gastroenterology. Wien Med Wochenschr Suppl 1975; 25: 18.
  • 24
    Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res 2009; 59: 13553.
  • 25
    Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients. Aliment Pharmacol Ther 2012; 36: 63543.
  • 26
    Jonasson C, Wernersson B, Hoff DA, Hatlebakk JG. Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2013; 37: 56472.
  • 27
    Dent J, Vakil N, Jones R et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut 2010; 59: 71421.
  • 28
    Bytzer P, Jones R, Vakil N et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10: 13606.
  • 29
    Moayyedi P, Axon AT. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 31225.
    Direct Link:
  • 30
    Weusten BL, Akkermans LM, van Berge-Henegouwen GP, Smout AJ. Symptom perception in gastroesophageal reflux disease is dependent on spatiotemporal reflux characteristics. Gastroenterology 1995; 108: 173944.
  • 31
    Savarino E, Marabotto E, Zentilin P et al. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis 2011; 43: 9405.
  • 32
    Guarino MP, Cheng L, Ma J et al. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol Motil 2010; 22: 74651, e219.
  • 33
    Ribolsi M, Emerenziani S, Petitti T, Addarii MC, Balestrieri P, Cicala M. Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responders to proton pump inhibitors. Dig Liver Dis 2012; 44: 54954.
  • 34
    Zerbib F, Belhocine K, Simon M et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut 2012; 61: 5016.
  • 35
    Pandolfino JE, Vela MF. Esophageal-reflux monitoring. Gastrointest Endosc 2009; 69: 91730.
  • 36
    Savarino E, Zentilin P, Frazzoni M et al. Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers. Neurogastroenterol Motil 2010; 22: 1061e280.
  • 37
    Zentilin P, Savarino V, Mastracci L et al. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol 2005; 100: 2299306.
    Direct Link:
  • 38
    Caviglia R, Ribolsi M, Maggiano N et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005; 100: 5438.
  • 39
    Savarino E, Zentilin P, Mastracci L et al. Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. J Gastroenterol 2013; 48: 47382.